2-phenyl-1,2-benzisothiazol-3-(2h)-one profile

2-phenyl-1,2-benzisothiazol-3-(2H)-one: structure given in first source; sulfur analog of ebselen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	164981
CHEMBL ID	45152
SCHEMBL ID	1898397
MeSH ID	M0168474

Synonym
2527-03-9
AG-690/40083036
2-phenyl-1,2-benzisothiazol-3(2h)-one
MLS-0107957.0001 ,
smr000163733
MLS000537191
2-phenyl-1,2-benzothiazol-3-one
1,2-benzisothiazol-3(2h)-one, 2-phenyl-
2-phenyl-3-thiaisoindolin-1-one
UNM-0000305795
pz 25
CHEMBL45152
KUC103442N
KUC103442N-2
NCGC00247195-01
SCHEMBL1898397
pz-25
2-phenyl-1,2-benzisothiazol-3-(2h)-one
rp 62373
rp-62373
pz25
2-phenyl-1,2-benzoisothiazol-3(2h)-one
HMS2355F10
ksc-325-052
KUC103442N-03
2-phenyl-1,2-benzisothiazol-3(2h)-on
cid_164981
bdbm46667
2-phenyl-1,2-benzothiazol-3-one (1)
DTXSID50179917
Z204268858
pd086291
2-phenyl-benzo[d]isothiazol-3-one
2-phenylbenzo[d]isothiazol-3(2h)-one
2-phenyl-2,3-dihydro-1,2-benzothiazol-3-one
EN300-124616
PD086290

Excerpt	Reference	Relevance
" The most promising compounds were also profiled for bioavailability parameters, including metabolic stability, plasma stability, and permeability."	( Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. Bravo, Y; Brown, B; Cosford, ND; Dahl, R; Dhanya, RP; Freeze, HH; Hedrick, M; Ichikawa, M; Mangravita-Novo, A; Rascon, J; Sergienko, E; Sharma, V; Smith, LH; Stonich, D; Su, Y; Vicchiarelli, M; Yang, L, 2011)	0.37

Excerpt	Relevance	Reference
" The pharmacokinetic profile of a representative of this series (compound 19; ML089) was also assessed, demonstrating the potential of this series for in vivo efficacy when dosed orally in disease models."	( Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. Bravo, Y; Brown, B; Cosford, ND; Dahl, R; Dhanya, RP; Freeze, HH; Hedrick, M; Ichikawa, M; Mangravita-Novo, A; Rascon, J; Sergienko, E; Sharma, V; Smith, LH; Stonich, D; Su, Y; Vicchiarelli, M; Yang, L, 2011)	0.37

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	0.3981	0.0040	23.8416	100.0000	AID485290
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	63.0957	0.0447	17.8581	100.0000	AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	12.5594	0.1409	11.1940	39.8107	AID2451
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	3.9811	0.6310	35.7641	100.0000	AID504339
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	25.1189	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	50.1187	5.6234	17.2929	31.6228	AID485281
Luciferase	Photinus pyralis (common eastern firefly)	Potency	7.5686	0.0072	15.7588	89.3584	AID588342
Nrf2	Homo sapiens (human)	Potency	17.7828	0.0920	8.2222	23.1093	AID624171
glp-1 receptor, partial	Homo sapiens (human)	Potency	10.0000	0.0184	6.8060	14.1254	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	14.1254	0.1000	20.8793	79.4328	AID588453
WRN	Homo sapiens (human)	Potency	50.1187	0.1683	31.2583	100.0000	AID651768
phosphopantetheinyl transferase	Bacillus subtilis	Potency	0.5012	0.1413	37.9142	100.0000	AID1490
ATAD5 protein, partial	Homo sapiens (human)	Potency	29.0929	0.0041	10.8903	31.5287	AID504467
GLS protein	Homo sapiens (human)	Potency	4.4668	0.3548	7.9355	39.8107	AID624170
TDP1 protein	Homo sapiens (human)	Potency	2.7511	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	13.5345	0.1800	13.5574	39.8107	AID1460; AID1468
Smad3	Homo sapiens (human)	Potency	15.8489	0.0052	7.8098	29.0929	AID588855
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	4.4668	0.0112	12.4002	100.0000	AID1030
hypothetical protein, conserved	Trypanosoma brucei	Potency	12.5893	0.2239	11.2451	35.4813	AID624173
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	56.2341	0.5318	15.4358	37.6858	AID504845
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	7.0795	0.2818	9.7212	35.4813	AID2326
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	7.9433	0.7079	36.9043	89.1251	AID504333
pyruvate kinase	Leishmania mexicana mexicana	Potency	39.8107	0.3981	13.7447	31.6228	AID1721; AID1722
IDH1	Homo sapiens (human)	Potency	20.5962	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	1.4125	0.0355	20.9770	89.1251	AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	31.6228	0.0165	25.3078	41.3999	AID602332
polyunsaturated fatty acid lipoxygenase ALOX12	Homo sapiens (human)	Potency	12.5893	1.0000	12.2326	31.6228	AID1452
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	0.5045	0.0018	15.6638	39.8107	AID2429; AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	3.9811	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	31.6228	0.0060	26.1688	89.1251	AID540317
pyruvate kinase PKM isoform a	Homo sapiens (human)	Potency	39.8107	0.0401	7.4590	31.6228	AID1631; AID1634
flap endonuclease 1	Homo sapiens (human)	Potency	89.1251	0.1337	25.4129	89.1251	AID588795
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	1.0621	0.1683	16.4040	67.0158	AID720504
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	35.4813	0.0501	27.0736	89.1251	AID588590
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	3.1832	0.0079	8.2332	1,122.0200	AID2546; AID2551
geminin	Homo sapiens (human)	Potency	10.3910	0.0046	11.3741	33.4983	AID624296; AID624297
Vpr	Human immunodeficiency virus 1	Potency	8.9125	1.5849	19.6264	63.0957	AID651644
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	1.0000	0.2512	15.8432	39.8107	AID504327
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	7.9433	0.0158	12.3113	615.5000	AID1461
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	1.2589	0.3162	12.7657	31.6228	AID881
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	7.0795	4.4668	8.3448	10.0000	AID624291
Endothelin receptor type B	Rattus norvegicus (Norway rat)	Potency	39.8107	0.5623	15.1609	31.6228	AID1721
Endothelin-1 receptor	Rattus norvegicus (Norway rat)	Potency	39.8107	0.5623	15.1609	31.6228	AID1721
Alpha-synuclein	Homo sapiens (human)	Potency	22.3872	0.5623	9.3985	25.1189	AID652106
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	1.2589	0.0063	8.2350	39.8107	AID881
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	35.4813	1.7783	16.2081	35.4813	AID652104
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	6.9454	0.0601	10.7453	37.9330	AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
MPI protein	Homo sapiens (human)	IC50 (µMol)	13.8250	0.1900	13.8256	50.1000	AID1535; AID1536
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase	Plasmodium berghei	IC50 (µMol)	6.2600	0.8890	21.0286	71.5000	AID504765; AID540252; AID540269
hexokinase	Trypanosoma brucei brucei TREU927	IC50 (µMol)	3.9563	0.2008	4.6024	22.3780	AID1632; AID2230
caspase recruitment domain family, member 15	Homo sapiens (human)	IC50 (µMol)	3.9990	0.6215	4.0504	6.6330	AID651553
phosphomannomutase 2	Homo sapiens (human)	IC50 (µMol)	36.9000	0.6720	34.7838	97.3000	AID1655
glucose-6-phosphate 1-dehydrogenase isoform b	Homo sapiens (human)	IC50 (µMol)	8.8700	8.8700	12.8518	17.8000	AID504792
phosphoethanolamine/phosphocholine phosphatase isoform 1	Homo sapiens (human)	IC50 (µMol)	0.9410	0.1110	0.5769	0.9410	AID1666
polyadenylate-binding protein 1	Homo sapiens (human)	IC50 (µMol)	66.0000	4.9100	23.7029	76.1900	AID602259; AID602260
receptor-interacting serine/threonine-protein kinase 2 isoform 1	Homo sapiens (human)	IC50 (µMol)	3.9990	0.6215	4.0504	6.6330	AID651553
eukaryotic translation initiation factor 4 gamma 1 isoform 4	Homo sapiens (human)	IC50 (µMol)	20.0657	1.1500	12.6200	25.6529	AID855
eukaryotic translation initiation factor 4E isoform 1	Mus musculus (house mouse)	IC50 (µMol)	20.0657	1.1500	12.6200	25.6529	AID855
DNA dC->dU-editing enzyme APOBEC-3G isoform 1	Homo sapiens (human)	IC50 (µMol)	6.4000	0.2700	26.3638	100.0000	AID504719
DNA dC->dU-editing enzyme APOBEC-3A isoform a	Homo sapiens (human)	IC50 (µMol)	100.0000	1.4800	14.5267	61.2000	AID504722
Phosphomannomutase 2	Homo sapiens (human)	IC50 (µMol)	20.0000	5.2000	5.2000	5.2000	AID1187643; AID597375
Neutrophil elastase	Homo sapiens (human)	IC50 (µMol)	1.1107	0.0063	2.0734	22.3780	AID2230
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	0.4900	0.0040	2.9266	9.9600	AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	0.4900	0.0002	2.4585	9.9600	AID1805801
Mannose-6-phosphate isomerase	Homo sapiens (human)	IC50 (µMol)	6.4000	0.7100	3.3175	6.4000	AID1187642; AID597374
Caspase-3	Homo sapiens (human)	IC50 (µMol)	0.5328	0.0002	1.1979	8.8000	AID752626
Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)	IC50 (µMol)	0.9400	0.5000	2.1343	5.2000	AID1187641
Beta lactamase (plasmid)	Pseudomonas aeruginosa	IC50 (µMol)	16.6340	0.7091	5.0549	7.7510	AID651552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RGS7, partial	Homo sapiens (human)	EC50 (µMol)	30.0000	0.1400	2.1300	4.7800	AID1871; AID2296
MSRA protein	Bos taurus (cattle)	EC50 (µMol)	79.2820	3.6370	4.0500	4.4630	AID623963
RGS8 protein	Homo sapiens (human)	EC50 (µMol)	30.0000	0.1270	0.3500	0.5730	AID2307
regulator of G-protein signaling 4	Homo sapiens (human)	EC50 (µMol)	15.0675	0.1350	3.3506	10.0690	AID1872; AID2295
regulator of G-protein signaling 19	Homo sapiens (human)	EC50 (µMol)	15.1600	0.1150	3.1756	14.1300	AID1884; AID2311
regulator of G-protein signaling 16	Homo sapiens (human)	EC50 (µMol)	15.8450	0.0530	3.6258	16.0000	AID1888; AID2298
streptokinase A precursor	Streptococcus pyogenes M1 GAS	EC50 (µMol)	75.5570	0.0600	8.9128	130.5170	AID1902; AID1914
Estrogen receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	150.0000	0.0060	22.3670	130.5170	AID1914
Mu-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	30.0000	0.0000	0.3263	9.4000	AID2311
Estrogen receptor beta	Rattus norvegicus (Norway rat)	EC50 (µMol)	150.0000	0.0060	22.3670	130.5170	AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
heat shock protein HSP 90-alpha isoform 2	Homo sapiens (human)	AC50	18.6960	0.1950	3.6679	18.6960	AID540270
heat shock protein 90, putative	Plasmodium falciparum 3D7	AC50	9.1920	0.1950	4.9920	98.5000	AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein glycosylation	Phosphomannomutase 2	Homo sapiens (human)
GDP-mannose biosynthetic process	Phosphomannomutase 2	Homo sapiens (human)
protein N-linked glycosylation	Phosphomannomutase 2	Homo sapiens (human)
mannose metabolic process	Phosphomannomutase 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
proteolysis	Neutrophil elastase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Neutrophil elastase	Homo sapiens (human)
response to yeast	Neutrophil elastase	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Neutrophil elastase	Homo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteria	Neutrophil elastase	Homo sapiens (human)
proteolysis	Neutrophil elastase	Homo sapiens (human)
intracellular calcium ion homeostasis	Neutrophil elastase	Homo sapiens (human)
response to UV	Neutrophil elastase	Homo sapiens (human)
extracellular matrix disassembly	Neutrophil elastase	Homo sapiens (human)
protein catabolic process	Neutrophil elastase	Homo sapiens (human)
response to lipopolysaccharide	Neutrophil elastase	Homo sapiens (human)
negative regulation of chemokine production	Neutrophil elastase	Homo sapiens (human)
negative regulation of interleukin-8 production	Neutrophil elastase	Homo sapiens (human)
positive regulation of interleukin-8 production	Neutrophil elastase	Homo sapiens (human)
defense response to bacterium	Neutrophil elastase	Homo sapiens (human)
positive regulation of MAP kinase activity	Neutrophil elastase	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Neutrophil elastase	Homo sapiens (human)
negative regulation of inflammatory response	Neutrophil elastase	Homo sapiens (human)
positive regulation of immune response	Neutrophil elastase	Homo sapiens (human)
negative regulation of chemotaxis	Neutrophil elastase	Homo sapiens (human)
pyroptosis	Neutrophil elastase	Homo sapiens (human)
neutrophil-mediated killing of gram-negative bacterium	Neutrophil elastase	Homo sapiens (human)
neutrophil-mediated killing of fungus	Neutrophil elastase	Homo sapiens (human)
positive regulation of leukocyte tethering or rolling	Neutrophil elastase	Homo sapiens (human)
phagocytosis	Neutrophil elastase	Homo sapiens (human)
acute inflammatory response to antigenic stimulus	Neutrophil elastase	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
GDP-mannose biosynthetic process	Mannose-6-phosphate isomerase	Homo sapiens (human)
mannose to fructose-6-phosphate catabolic process	Mannose-6-phosphate isomerase	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Mu-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
sensory perception	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Mu-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
behavioral response to ethanol	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of neurogenesis	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of Wnt protein secretion	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mu-type opioid receptor	Homo sapiens (human)
calcium ion transmembrane transport	Mu-type opioid receptor	Homo sapiens (human)
cellular response to morphine	Mu-type opioid receptor	Homo sapiens (human)
regulation of cellular response to stress	Mu-type opioid receptor	Homo sapiens (human)
regulation of NMDA receptor activity	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
calcium ion homeostasis	Alpha-synuclein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Alpha-synuclein	Homo sapiens (human)
microglial cell activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of receptor recycling	Alpha-synuclein	Homo sapiens (human)
positive regulation of neurotransmitter secretion	Alpha-synuclein	Homo sapiens (human)
negative regulation of protein kinase activity	Alpha-synuclein	Homo sapiens (human)
fatty acid metabolic process	Alpha-synuclein	Homo sapiens (human)
neutral lipid metabolic process	Alpha-synuclein	Homo sapiens (human)
phospholipid metabolic process	Alpha-synuclein	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial membrane organization	Alpha-synuclein	Homo sapiens (human)
adult locomotory behavior	Alpha-synuclein	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-synuclein	Homo sapiens (human)
response to iron(II) ion	Alpha-synuclein	Homo sapiens (human)
regulation of phospholipase activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
regulation of glutamate secretion	Alpha-synuclein	Homo sapiens (human)
regulation of dopamine secretion	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle exocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle priming	Alpha-synuclein	Homo sapiens (human)
regulation of transmembrane transporter activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of microtubule polymerization	Alpha-synuclein	Homo sapiens (human)
receptor internalization	Alpha-synuclein	Homo sapiens (human)
protein destabilization	Alpha-synuclein	Homo sapiens (human)
response to magnesium ion	Alpha-synuclein	Homo sapiens (human)
negative regulation of transporter activity	Alpha-synuclein	Homo sapiens (human)
response to lipopolysaccharide	Alpha-synuclein	Homo sapiens (human)
negative regulation of monooxygenase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Alpha-synuclein	Homo sapiens (human)
response to type II interferon	Alpha-synuclein	Homo sapiens (human)
cellular response to oxidative stress	Alpha-synuclein	Homo sapiens (human)
SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
positive regulation of SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
regulation of locomotion	Alpha-synuclein	Homo sapiens (human)
dopamine biosynthetic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial ATP synthesis coupled electron transport	Alpha-synuclein	Homo sapiens (human)
regulation of macrophage activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of endocytosis	Alpha-synuclein	Homo sapiens (human)
negative regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
positive regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle endocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle transport	Alpha-synuclein	Homo sapiens (human)
positive regulation of inflammatory response	Alpha-synuclein	Homo sapiens (human)
regulation of acyl-CoA biosynthetic process	Alpha-synuclein	Homo sapiens (human)
protein tetramerization	Alpha-synuclein	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Alpha-synuclein	Homo sapiens (human)
neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of serotonin uptake	Alpha-synuclein	Homo sapiens (human)
regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
negative regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
excitatory postsynaptic potential	Alpha-synuclein	Homo sapiens (human)
long-term synaptic potentiation	Alpha-synuclein	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
response to interleukin-1	Alpha-synuclein	Homo sapiens (human)
cellular response to copper ion	Alpha-synuclein	Homo sapiens (human)
cellular response to epinephrine stimulus	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber organization	Alpha-synuclein	Homo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinone	Alpha-synuclein	Homo sapiens (human)
positive regulation of glutathione peroxidase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of hydrogen peroxide catabolic process	Alpha-synuclein	Homo sapiens (human)
regulation of synaptic vesicle recycling	Alpha-synuclein	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein localization to cell periphery	Alpha-synuclein	Homo sapiens (human)
negative regulation of chaperone-mediated autophagy	Alpha-synuclein	Homo sapiens (human)
regulation of presynapse assembly	Alpha-synuclein	Homo sapiens (human)
amyloid fibril formation	Alpha-synuclein	Homo sapiens (human)
synapse organization	Alpha-synuclein	Homo sapiens (human)
chemical synaptic transmission	Alpha-synuclein	Homo sapiens (human)
neurotrophin TRK receptor signaling pathway	Caspase-3	Homo sapiens (human)
luteolysis	Caspase-3	Homo sapiens (human)
response to hypoxia	Caspase-3	Homo sapiens (human)
B cell homeostasis	Caspase-3	Homo sapiens (human)
negative regulation of cytokine production	Caspase-3	Homo sapiens (human)
proteolysis	Caspase-3	Homo sapiens (human)
apoptotic process	Caspase-3	Homo sapiens (human)
DNA damage response	Caspase-3	Homo sapiens (human)
axonal fasciculation	Caspase-3	Homo sapiens (human)
heart development	Caspase-3	Homo sapiens (human)
sensory perception of sound	Caspase-3	Homo sapiens (human)
learning or memory	Caspase-3	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stress	Caspase-3	Homo sapiens (human)
response to xenobiotic stimulus	Caspase-3	Homo sapiens (human)
response to UV	Caspase-3	Homo sapiens (human)
response to wounding	Caspase-3	Homo sapiens (human)
response to glucose	Caspase-3	Homo sapiens (human)
response to X-ray	Caspase-3	Homo sapiens (human)
regulation of macroautophagy	Caspase-3	Homo sapiens (human)
protein processing	Caspase-3	Homo sapiens (human)
hippocampus development	Caspase-3	Homo sapiens (human)
protein catabolic process	Caspase-3	Homo sapiens (human)
erythrocyte differentiation	Caspase-3	Homo sapiens (human)
platelet formation	Caspase-3	Homo sapiens (human)
negative regulation of B cell proliferation	Caspase-3	Homo sapiens (human)
regulation of protein stability	Caspase-3	Homo sapiens (human)
response to cobalt ion	Caspase-3	Homo sapiens (human)
response to estradiol	Caspase-3	Homo sapiens (human)
response to lipopolysaccharide	Caspase-3	Homo sapiens (human)
glial cell apoptotic process	Caspase-3	Homo sapiens (human)
response to tumor necrosis factor	Caspase-3	Homo sapiens (human)
response to nicotine	Caspase-3	Homo sapiens (human)
response to hydrogen peroxide	Caspase-3	Homo sapiens (human)
T cell homeostasis	Caspase-3	Homo sapiens (human)
response to amino acid	Caspase-3	Homo sapiens (human)
fibroblast apoptotic process	Caspase-3	Homo sapiens (human)
cell fate commitment	Caspase-3	Homo sapiens (human)
negative regulation of cell cycle	Caspase-3	Homo sapiens (human)
negative regulation of activated T cell proliferation	Caspase-3	Homo sapiens (human)
striated muscle cell differentiation	Caspase-3	Homo sapiens (human)
response to glucocorticoid	Caspase-3	Homo sapiens (human)
neuron apoptotic process	Caspase-3	Homo sapiens (human)
protein maturation	Caspase-3	Homo sapiens (human)
anterior neural tube closure	Caspase-3	Homo sapiens (human)
pyroptosis	Caspase-3	Homo sapiens (human)
leukocyte apoptotic process	Caspase-3	Homo sapiens (human)
cellular response to staurosporine	Caspase-3	Homo sapiens (human)
apoptotic signaling pathway	Caspase-3	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Caspase-3	Homo sapiens (human)
execution phase of apoptosis	Caspase-3	Homo sapiens (human)
positive regulation of pyroptosis	Caspase-3	Homo sapiens (human)
positive regulation of amyloid-beta formation	Caspase-3	Homo sapiens (human)
epithelial cell apoptotic process	Caspase-3	Homo sapiens (human)
keratinocyte differentiation	Caspase-3	Homo sapiens (human)
positive regulation of neuron apoptotic process	Caspase-3	Homo sapiens (human)
neuron differentiation	Caspase-3	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
endochondral ossification	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
bone mineralization	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
regulation of bone mineralization	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
bone mineralization involved in bone maturation	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phosphomannomutase activity	Phosphomannomutase 2	Homo sapiens (human)
protein binding	Phosphomannomutase 2	Homo sapiens (human)
metal ion binding	Phosphomannomutase 2	Homo sapiens (human)
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protease binding	Neutrophil elastase	Homo sapiens (human)
transcription corepressor activity	Neutrophil elastase	Homo sapiens (human)
endopeptidase activity	Neutrophil elastase	Homo sapiens (human)
serine-type endopeptidase activity	Neutrophil elastase	Homo sapiens (human)
protein binding	Neutrophil elastase	Homo sapiens (human)
heparin binding	Neutrophil elastase	Homo sapiens (human)
peptidase activity	Neutrophil elastase	Homo sapiens (human)
cytokine binding	Neutrophil elastase	Homo sapiens (human)
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mannose-6-phosphate isomerase activity	Mannose-6-phosphate isomerase	Homo sapiens (human)
zinc ion binding	Mannose-6-phosphate isomerase	Homo sapiens (human)
G-protein alpha-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor activity	Mu-type opioid receptor	Homo sapiens (human)
beta-endorphin receptor activity	Mu-type opioid receptor	Homo sapiens (human)
voltage-gated calcium channel activity	Mu-type opioid receptor	Homo sapiens (human)
protein binding	Mu-type opioid receptor	Homo sapiens (human)
morphine receptor activity	Mu-type opioid receptor	Homo sapiens (human)
G-protein beta-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Mu-type opioid receptor	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
protease binding	Caspase-3	Homo sapiens (human)
aspartic-type endopeptidase activity	Caspase-3	Homo sapiens (human)
cysteine-type endopeptidase activity	Caspase-3	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activity	Caspase-3	Homo sapiens (human)
death receptor binding	Caspase-3	Homo sapiens (human)
protein binding	Caspase-3	Homo sapiens (human)
peptidase activity	Caspase-3	Homo sapiens (human)
phospholipase A2 activator activity	Caspase-3	Homo sapiens (human)
protein-containing complex binding	Caspase-3	Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic process	Caspase-3	Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathway	Caspase-3	Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosis	Caspase-3	Homo sapiens (human)
enzyme activator activity	Caspase-3	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
pyrophosphatase activity	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
metal ion binding	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
phosphocholine phosphatase activity	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
phosphoethanolamine phosphatase activity	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
phosphatase activity	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
nucleoplasm	Phosphomannomutase 2	Homo sapiens (human)
cytosol	Phosphomannomutase 2	Homo sapiens (human)
neuronal cell body	Phosphomannomutase 2	Homo sapiens (human)
cytosol	Phosphomannomutase 2	Homo sapiens (human)
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular region	Neutrophil elastase	Homo sapiens (human)
extracellular space	Neutrophil elastase	Homo sapiens (human)
cytoplasm	Neutrophil elastase	Homo sapiens (human)
cytosol	Neutrophil elastase	Homo sapiens (human)
cell surface	Neutrophil elastase	Homo sapiens (human)
secretory granule	Neutrophil elastase	Homo sapiens (human)
azurophil granule lumen	Neutrophil elastase	Homo sapiens (human)
specific granule lumen	Neutrophil elastase	Homo sapiens (human)
phagocytic vesicle	Neutrophil elastase	Homo sapiens (human)
collagen-containing extracellular matrix	Neutrophil elastase	Homo sapiens (human)
extracellular exosome	Neutrophil elastase	Homo sapiens (human)
transcription repressor complex	Neutrophil elastase	Homo sapiens (human)
extracellular space	Neutrophil elastase	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cytosol	Mannose-6-phosphate isomerase	Homo sapiens (human)
extracellular exosome	Mannose-6-phosphate isomerase	Homo sapiens (human)
cytosol	Mannose-6-phosphate isomerase	Homo sapiens (human)
endosome	Mu-type opioid receptor	Homo sapiens (human)
endoplasmic reticulum	Mu-type opioid receptor	Homo sapiens (human)
Golgi apparatus	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
axon	Mu-type opioid receptor	Homo sapiens (human)
dendrite	Mu-type opioid receptor	Homo sapiens (human)
perikaryon	Mu-type opioid receptor	Homo sapiens (human)
synapse	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
neuron projection	Mu-type opioid receptor	Homo sapiens (human)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
nucleus	Caspase-3	Homo sapiens (human)
cytoplasm	Caspase-3	Homo sapiens (human)
nucleus	Caspase-3	Homo sapiens (human)
nucleoplasm	Caspase-3	Homo sapiens (human)
cytosol	Caspase-3	Homo sapiens (human)
neuronal cell body	Caspase-3	Homo sapiens (human)
death-inducing signaling complex	Caspase-3	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
extracellular membrane-bounded organelle	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
cytosol	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
extracellular matrix	Phosphoethanolamine/phosphocholine phosphatase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (104)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1324762	Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 at 0.5 times MIC measured after 24 hrs by time kill analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430047	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method
AID1324759	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430056	Anti-fungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution method
AID1324756	Antibacterial activity against Enterobacter cloacae ATCC 13047 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430048	Antibacterial activity against Escherichia coli ATCC 9637 by broth microdilution method
AID1324746	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430053	Anti-fungal activity against Sporothrix schenckii after 48 hrs by broth microdilution method
AID1822761	Cytotoxicity against human HaCaT cells	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1430046	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by broth microdilution method
AID1324720	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430052	Anti-fungal activity against Cryptococcus neoformans after 48 hrs by broth microdilution method
AID1324750	Antibacterial activity against Enterococcus faecalis ATCC 49533 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430050	Antibacterial activity against Klebsiella pneumoniae ATCC 27736 by broth microdilution method
AID1324738	Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS51 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324744	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324747	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA600 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1187641	Inhibition of PHOSPHO1 phosphoethanolamine activity (unknown origin) assessed as amount of inorganic phosphate release after 30 mins	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
AID1324785	Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 using 1 10'6CFU/ml measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324726	Antibacterial activity against methicillin-resistant Staphylococcus aureus BRS3 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324739	Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS77 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1514494	Selectivity index, ratio of IC50 for HEK293T cells to IC50 for Trypanosoma brucei brucei AnTat1.1E	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria.
AID1324724	Antibacterial activity against methicillin-resistant Staphylococcus aureus 1 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1187642	Inhibition of phosphomannose isomerase (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
AID1430055	Anti-fungal activity against Aspergillus fumigatus after 48 hrs by broth microdilution method
AID1324754	Antibacterial activity against Mycobacterium smegmatis MC2-155 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324727	Antibacterial activity against methicillin-resistant Staphylococcus aureus C1 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430059	Cytotoxicity against monkey Vero C1008 cells after 72 hrs by MTT assay
AID1324782	Antibacterial activity against Staphylococcus epidermidis ATCC 35984 assessed as induction of membrane disruption at 1 and 4 times MIC measured after 1 hr by propidium iodide staining-based fluorescence microscopic analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324733	Antibacterial activity against methicillin-resistant Staphylococcus aureus G1 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1187643	Inhibition of PMM2 (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
AID1324723	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324753	Antibacterial activity against Listeria monocytogenes ATCC 19115 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID597375	Inhibition of human purified PMM2	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia.
AID1324749	Antibacterial activity against Enterococcus faecalis ATCC 29212 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324729	Antibacterial activity against methicillin-resistant Staphylococcus aureus C7 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430049	Antibacterial activity against Pseudomonas aeruginosa ATCC BAA-427 by broth microdilution method
AID1324737	Antibacterial activity against methicillin-resistant Staphylococcus aureus NRS4 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324755	Antibacterial activity against Acinetobacter baumannii ATCC 19606 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID597374	Inhibition of human purified phosphomannose isomerase	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia.
AID1686310	Binding affinity to GST-tagged human TMPK expressed in Escherichia coli BL21 assessed as formation of disulfide bonds with Cys residues incubated for 30 mins at 25 degC in presence of trypsin by LC-MS/MS analysis	2016	Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21	Chemical Inhibition of Human Thymidylate Kinase and Structural Insights into the Phosphate Binding Loop and Ligand-Induced Degradation.
AID1324730	Antibacterial activity against methicillin-resistant Staphylococcus aureus C14 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID171444	The compound was tested ex vivo at a dose of 0.15 mmol/kg for collagen induced platelet aggregation in rat	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1430051	Anti-fungal activity against Candida albicans after 48 hrs by broth microdilution method
AID1324751	Antibacterial activity against Enterococcus faecium BM4105-RF measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430058	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by SYBR Green-1 staining based fluorescence assay
AID74744	The compound was tested ex vivo at a dose of 0.15 mmol/kg for collagen induced platelet aggregation in guinea pig; ND=No data	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1430054	Anti-fungal activity against Trichophyton mentagrophytes after 48 hrs by broth microdilution method
AID1324763	Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at 0.5 times MIC measured up to 3 to 6 hrs by time kill analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324784	Inhibition of thioredoxin reductase in Staphylococcus epidermidis ATCC 35984 assessed as induction of ROS production at 1 to 4 times MIC measured after 1 hr by DCFH-DA staining-based fluorescence microscopic analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1430060	Selectivity index, ratio of CC50 for monkey Vero C1008 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7
AID1514498	Selectivity index, ratio of IC50 for HEK293T cells to IC50 for Trypanosoma brucei gambiense MBA	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria.
AID1430045	Antibacterial activity against Staphylococcus aureus ATCC 25923 by broth microdilution method
AID1324742	Antibacterial activity against methicillin-resistant Staphylococcus aureus S22 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324748	Antibacterial activity against Staphylococcus epidermidis ATCC 35984 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324731	Antibacterial activity against methicillin-resistant Staphylococcus aureus C16 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324769	Antibiofilm activity against methicillin-sensitive Staphylococcus aureus ATCC 6538 assessed as reduction of biofilm at 31.3 ug/ml measured after 24 hrs by crystal violet staining based method relative to control	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID171442	The compound was tested ex vivo at a dose of 0.15 mmol/kg for ADP induced platelet aggregation in rat	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1822756	Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) incubated for 3 mins in presence of NADH by spectrophotometric analysis	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1324743	Antibacterial activity against methicillin-resistant Staphylococcus aureus S24 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324740	Antibacterial activity against methicillin-resistant Staphylococcus aureus S14 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324725	Antibacterial activity against methicillin-resistant Staphylococcus aureus 2 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1514493	Anti-parasitic activity against Trypanosoma brucei brucei AnTat1.1E	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria.
AID752626	Inhibition of recombinant human caspase-3 using Ac-LDEVD-AMC as substrate assessed as accumulation of 7-AMC incubated for 10 mins followed by substrate addition measured for 10 mins by fluorimetric analysis	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors.
AID1324721	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324752	Antibacterial activity against Vancomycin-resistant Enterococcus measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1514496	Selectivity index, ratio of IC50 for HEK293T cells to IC50 for Trypanosoma brucei rhodesiense STIB 851	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria.
AID74741	The compound was tested ex vivo at a dose of 0.15 mmol/kg for ADP induced platelet aggregation in guinea pig; ND=No data	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen.
AID1514497	Anti-parasitic activity against Trypanosoma brucei gambiense MBA	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria.
AID1324775	Antibiofilm activity against Staphylococcus epidermidis ATCC 35984 assessed as reduction of biofilm at 125 ug/ml measured after 24 hrs by crystal violet staining based method relative to control	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324757	Antibacterial activity against Escherichia coli MC1061 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1514495	Anti-parasitic activity against Trypanosoma brucei rhodesiense STIB 851	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria.
AID1324722	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 29213 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324761	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324732	Antibacterial activity against methicillin-resistant Staphylococcus aureus C19 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324734	Antibacterial activity against methicillin-resistant Staphylococcus aureus G6 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324780	Cytotoxicity against mouse RBCs assessed as hemolysis at 0.24 to 31.2 ug/ml measured after 1 hr	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324741	Antibacterial activity against methicillin-resistant Staphylococcus aureus S17 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324764	Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at MIC measured up to 3 to 6 hrs by time kill analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324736	Antibacterial activity against methicillin-resistant Staphylococcus aureus G14 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324778	Cytotoxicity against mouse RBCs assessed as hemolysis up to 7.8 ug/ml measured after 1 hr	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324758	Antibacterial activity against Klebsiella pneumoniae ATCC 27736 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324745	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA200 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324760	Antibacterial activity against Salmonella enterica ATCC 14028 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324766	Bacteriostatic activity against methicillin-resistant Staphylococcus aureus S22 at 4 times MIC measured after 24 hrs by time kill analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1434674	Antitrypanosomal activity against Trypanosoma brucei bloodstream forms after 72 hrs by CellTiter-Blue fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1434673	Inhibition of recombinant Trypanosoma brucei His6-tagged HK1 expressed in Escherichia coli M15(pREP) harboring pQE30 using glucose as substrate after 2 hrs by spectrophotometric based glucose 6-phosphate dehydrogenase enzyme coupled assay	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1324735	Antibacterial activity against methicillin-resistant Staphylococcus aureus G12 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1324728	Antibacterial activity against methicillin-resistant Staphylococcus aureus C2 measured after overnight incubation by broth double-dilution method	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus.
AID1805801	Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1800476	EMSA from Article 10.1021/cb500512z: \\Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication\\	2014	ACS chemical biology, Oct-17, Volume: 9, Issue:10	Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (8.70)	18.7374
1990's	4 (17.39)	18.2507
2000's	1 (4.35)	29.6817
2010's	13 (56.52)	24.3611
2020's	3 (13.04)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.35%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (95.65%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
histamine [no description available]	1.97	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
thioctic acid Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.	2.41	1	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
catechin [no description available]	2.31	1	hydroxyflavan
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate [no description available]	2.31	1	catechin
theophylline [no description available]	2.31	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	1.96	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
bronopol [no description available]	2.31	1	nitro compound
caffeine [no description available]	2.31	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
N-[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]carbamic acid (phenylmethyl) ester [no description available]	2.31	1	leucine derivative
carmofur [no description available]	2.76	2	organohalogen compound; pyrimidines
disulfiram [no description available]	2.76	2	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	3.81	11	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.63	2	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.	1.97	1	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.	2.31	1	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.31	1	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.97	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iodoacetamide [no description available]	2.1	1
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	2.31	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.	2.31	1	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	2.1	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	2.31	1	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	1.97	1	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
protoporphyrin ix protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.	2.31	1
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.31	1	indoles
alkannin [no description available]	2.31	1	naphthoquinone
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	1.96	1	pyrazolidines; sulfoxide	uricosuric drug
triclosan [no description available]	2.31	1	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
dithionitrobenzoic acid Dithionitrobenzoic Acid: A standard reagent for the determination of reactive sulfhydryl groups by absorbance measurements. It is used primarily for the determination of sulfhydryl and disulfide groups in proteins. The color produced is due to the formation of a thio anion, 3-carboxyl-4-nitrothiophenolate.. dithionitrobenzoic acid : An organic disulfide that results from the formal oxidative dimerisation of 2-nitro-5-thiobenzoic acid. An indicator used to quantify the number or concentration of thiol groups.	2.13	1	nitrobenzoic acid; organic disulfide	indicator
pyromellitic acid pyromellitic acid: RN given refers to parent cpd; structure. pyromellitic acid : A tetracarboxylic acid that is benzene substituted by four carboxy groups at positions 1, 2, 4 and 5 respectively.	2.31	1	benzoic acids; tetracarboxylic acid
chloranil Chloranil: A quinone fungicide used for treatment of seeds and foliage.. tetrachloro-1,4-benzoquinone : A member of the class of 1,4-benzoquiones that is 1,4-benzoquinone in which all four hydrogens are substituted by chlorines.	2.31	1	1,4-benzoquinones; organochlorine compound	EC 2.7.1.33 (pantothenate kinase) inhibitor; metabolite
nithiamide [no description available]	3.31	1	acetamides; aromatic amide
ditiocarb Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.	1.97	1	dithiocarbamic acids	chelator; copper chelator
thiazoles [no description available]	3.24	6	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
plumbagin plumbagin: a superoxide anion generator. plumbagin : A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.	2.31	1	hydroxy-1,4-naphthoquinone; phenols	anticoagulant; antineoplastic agent; immunological adjuvant; metabolite
dithiol dithiol: structure	2.31	1
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	2.31	1	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
abietic acid abietic acid : An abietane diterpenoid that is abieta-7,13-diene substituted by a carboxy group at position 18.	2.31	1	abietane diterpenoid; monocarboxylic acid	plant metabolite
4-(dimethylamino)benzoic acid [no description available]	2.31	1
agaric acid agaric acid: adenine nucleotide translocase antagonist	2.31	1
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	1.97	1	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
phenethyl isothiocyanate phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.	2.31	1	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite
1,2-benzisothiazoline-3-one 1,2-benzisothiazoline-3-one: a preservative in water-based solutions such as paints, cutting fluids, printing inks, cleaning agents, polyvinyl chloride gloves, etc.. benzo[d]isothiazol-3-one : An organic heterobicyclic compound based on a fused 1,2-thiazole and benzene bicyclic ring skeleton, with the S atom positioned adjacent to one of the positions of ring fusion.	2.97	4	organic heterobicyclic compound; organonitrogen heterocyclic compound	disinfectant; drug allergen; environmental contaminant; platelet aggregation inhibitor; sensitiser; xenobiotic
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.38	2	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2.13	1	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	2.15	1	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
zinc ethylphenyldithiocarbamate [no description available]	2.31	1
baicalin [no description available]	2.31	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose pentagalloylglucose: pentahydroxy gallic acid ester of glucose; a phytogenic antineoplastic agent and antibacterial agent. 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose : A galloyl-beta-D-glucose compound having five galloyl groups in the 1-, 2-, 3-, 4- and 6-positions.	2.31	1	gallate ester; galloyl beta-D-glucose	anti-inflammatory agent; antineoplastic agent; geroprotector; hepatoprotective agent; plant metabolite; radiation protective agent; radical scavenger
ticlopidine hydrochloride [no description available]	1.96	1	hydrochloride
masoprocol Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.	1.97	1	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
vanitiolide [no description available]	2.31	1	methoxybenzenes; phenols
LSM-4272 [no description available]	2.31	1	beta-carbolines
lopinavir [no description available]	2.31	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
zpck ZPCK: alkylates histidine residue at active center of bovine chymotrypsin	2.31	1
tingenone tingenone: quinonoid triterpene isolated from Euonymus tingens	2.31	1
tanshinone tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent	2.31	1	abietane diterpenoid	anticoronaviral agent
celastrol [no description available]	2.31	1	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	2.31	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
celastrol methyl ester celastrol methyl ester: isolated from Tripterygium wilfordii; potent inhibitory activity on both Kir2.1 and ERG1 potassium channels, leading to LONG QT SYNDROME	2.31	1	carboxylic ester
miltirone miltirone: from Salvis miltiorrhiza Bunge; central benzodiazepine receptor ligand; structure given in first source	2.31	1	abietane diterpenoid
cryptotanshinone cryptotanshinone: from Salvia miltiorrhiza	2.31	1	abietane diterpenoid	anticoronaviral agent
tanshinone ii a tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source	2.31	1	abietane diterpenoid
carboxyebselen carboxyebselen: a nitric oxide synthase inhibitor	2.94	3
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	2.31	1	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
1-methylpropyl-2-imidazolyl disulfide 1-methylpropyl-2-imidazolyl disulfide: a thioredoxin inhibitor with antineoplastic activity	2.31	1	imidazoles
nsc 95397 [no description available]	2.31	1	1,4-naphthoquinones
nsc 663284 NSC 663284: structure in first source	2.31	1	quinolone
bortezomib [no description available]	2.41	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	2.31	1	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
ferruginol ferruginol: structure in first source. ferruginol : An abietane diterpenoid that is abieta-8,11,13-triene substituted by a hydroxy group at positions 12.	2.31	1	abietane diterpenoid; carbotricyclic compound; meroterpenoid; phenols	antibacterial agent; antineoplastic agent; plant metabolite; protective agent
isopimaric acid isopimaric acid: isolated from the bark of Illicium jadifengpi	2.31	1	carbotricyclic compound; diterpenoid; monocarboxylic acid
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	2.31	1	aldehyde; tripeptide	cysteine protease inhibitor
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	1.97	1	tripeptide
gw 3965 GW 3965: a liver X receptor ligand	2.31	1	diarylmethane
benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.	2.31	1	amino aldehyde; carbamate ester; tripeptide	proteasome inhibitor
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.31	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide [no description available]	2.31	1	indolecarboxamide	anticoronaviral agent
dimethyl fumarate [no description available]	2.41	1	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator
acetyl-aspartyl-glutamyl-valyl-aspartal acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor. Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7.	2.08	1	tetrapeptide	protease inhibitor
1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source	2.31	1	methoxybenzenes
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.31	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
6-fluoro-2-phenyl-1,2-benzothiazol-3-one [no description available]	2.1	1	benzothiazoles
6-fluoro-2-(2-methylphenyl)-1,2-benzothiazol-3-one [no description available]	2.06	1	benzothiazoles
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	2.31	1	cinnamate ester; tannin	food component; plant metabolite
2-[4-methyl-3-(1-piperidinylsulfonyl)phenyl]-1,2-benzothiazol-3-one [no description available]	2.1	1	sulfonamide
5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine [no description available]	2.31	1	sulfonic acid derivative	anticoronaviral agent
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate [no description available]	2.31	1	acetylenic compound; furans; organofluorine compound; thioester; triazoles
telaprevir [no description available]	2.31	1	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
2-methylselenobenzanilide 2-methylselenobenzanilide: metabolite of ebselen	1.98	1
N-(4-Butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide [no description available]	2.31	1	aromatic amide; furans	anticoronaviral agent
8-(Trifluoromethyl)-9H-purin-6-amine [no description available]	2.31	1	6-aminopurines	anticoronaviral agent
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.31	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
suramin sodium suramin(6-) : An organosulfate oxoanion that is the hexanion of suramin resulting from the deprotonation of the six sulfo groups; major species at pH 7.3.	2.31	1	organosulfate oxoanion
2-[[3-(3-oxo-1,2-benzothiazol-2-yl)phenyl]sulfonylamino]benzoic acid [no description available]	2.1	1	sulfonamide
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	2.76	2	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	2.31	1	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
N,N-dimethyl-3-(3-oxo-1,2-benzothiazol-2-yl)benzenesulfonamide [no description available]	2.1	1	sulfonamide
ginkgetin ginkgetin: from Cephalotaxus drupacea; biflavone; active against HSV-1; structure given in first source. ginkgetin : A biflavonoid that is the 7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2.	2.31	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	anti-HSV-1 agent; antineoplastic agent; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; metabolite
quercetin [no description available]	2.31	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.31	1	trihydroxyflavone	antineoplastic agent; metabolite
luteolin [no description available]	2.31	1	3'-hydroxyflavonoid; tetrahydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist
amentoflavone [no description available]	2.31	1	biflavonoid; hydroxyflavone; ring assembly	angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite
baicalein [no description available]	2.31	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
sciadopitysin sciadopitysin: biflavonoid from Taxus celebica & Ginkgo biloba. sciadopitysin : A biflavonoid that is a 7, 4', 4'''-trimethyl ether derivative of amentoflavone.	2.31	1	biflavonoid; hydroxyflavone; methoxyflavone; ring assembly	bone density conservation agent; platelet aggregation inhibitor
scutellarein scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.	2.31	1	tetrahydroxyflavone	metabolite
benzyloxycarbonyl-phe-ala-fluormethylketone cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).	2.31	1
bilobetin bilobetin: a phospholipase A2 antagonist	2.31	1	flavonoid oligomer
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	2.31	1	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
cinanserin Cinanserin: A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity.. cinanserin : An aryl sulfide that is (2E)-3-phenyl-N-(2-sulfanylphenyl)prop-2-enamide in which the hydrogen of the thiol group is substituted by a 3-(dimethylamino)propyl group. It is a 5-hydroxytryptamine receptor antagonist and an inhibitor of SARS-CoV replication.	2.31	1	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide : A tripeptide resulting from the formal condensation of the carboxy group of N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valine with the amino group of benzyl (2E,4S)-4-(L-leucylamino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate. It is an inhibitor of the main protease of SARS-CoV-2.	2.31	1	benzyl ester; isoxazoles; pyrrolidin-2-ones; tripeptide	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
selenium Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.	2.89	4	chalcogen; nonmetal atom	micronutrient
4-isopropylbenzaldehyde thiosemicarbazone 4-isopropylbenzaldehyde thiosemicarbazone: structure in first source	3.31	1
Ethyl (E,4S)-4-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-phenylpropanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate [no description available]	2.31	1	dipeptide	anticoronaviral agent
mdl 201053 MDL 201053: Immunosuppressive Agent; RN given refers to compound with no isomeric designation	2.31	1
5-Chloro-3-pyridinyl 2-furoate [no description available]	2.31	1	carboxylic ester	anticoronaviral agent
sp 100030 N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide: transcription factor inhibitor specific to T-cells	2.31	1
gw0742 GW 610742: structure in first source	2.31	1	monocarboxylic acid
benzyloxycarbonyl-isoleucyl-glutamyl(o-tert-butyl)-alanyl-leucinal benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal: inhibits chymotrypsin activity of the proteasome	2.31	1
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.31	1	organic cation
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide boceprevir : A synthetic tripeptide consisting of N-(tert-butylcarbamoyl)-3-methyl-L-valyl, a cyclopropyl-fused prolyl and 3-amino-4-cyclobutyl-2-oxobutanamide residues joined in sequence. Used for treatment of chronic hepatitis C virus genotype 1 infection.	2.31	1	tripeptide; ureas	antiviral drug; hepatitis C protease inhibitor; peptidomimetic
triptohypol C triptohypol C : A pentacyclic triterpenoid with formula C29H40O4, originally isolated from the root bark of Tripterygium regelii.	2.31	1	benzenediols; monocarboxylic acid; pentacyclic triterpenoid	apoptosis inducer; plant metabolite
2-(4-chlorophenyl)-1,2-benzothiazol-3-one [no description available]	2.82	3	benzothiazoles
np 031112 tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.	2.31	1	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
Dihydrotanshinone I dihydrotanshinone I: extracted from Radix Salviae	2.31	1	abietane diterpenoid	anticoronaviral agent
mk-0893 [no description available]	2.31	1
2-(3-chlorophenyl)-1,2-benzothiazol-3-one [no description available]	2.48	2	benzothiazoles
Benzotriazol-1-yl 1H-indole-5-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
tannins gallotannin : A class of hydrolysable tannins obtained by condensation of the carboxy group of gallic acid (and its polymeric derivatives) with the hydroxy groups of a monosaccharide (most commonly glucose).	2.31	1	tannin
oritavancin oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.	2.31	1	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent
5-Bromopyridin-3-yl furan-2-carboxylate [no description available]	2.31	1	carboxylic ester	anticoronaviral agent
(5-Chloropyridin-3-yl) 1H-indole-5-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
5-Chloropyridin-3-yl 1H-indole-2-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
phenylmercuric acetate Phenylmercuric Acetate: A phenyl mercury compound used mainly as a fungicide. Has also been used as a herbicide, slimicide, and bacteriocide.	2.31	1	arylmercury compound; benzenes
thimerosal Thimerosal: An ethylmercury-sulfidobenzoate that has been used as a preservative in VACCINES; ANTIVENINS; and OINTMENTS. It was formerly used as a topical antiseptic. It degrades to ethylmercury and thiosalicylate.. thimerosal : An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.	2.31	1	alkylmercury compound	antifungal drug; antiseptic drug; disinfectant; drug allergen
5-fluoro-2-phenyl-1,2-benzothiazol-3-one [no description available]	2.06	1	benzothiazoles
2-(4-fluorophenyl)-1,2-benzothiazol-3-one [no description available]	2.52	2	benzothiazoles
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate [no description available]	2.31	1	indolyl carboxylic acid	anticoronaviral agent
Benzyl N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]-1-(1,3-thiazol-2-yl)propan-2-yl]amino]pentan-2-yl]amino]-1-oxobutan-2-yl]carbamate [no description available]	2.31	1	dipeptide	anticoronaviral agent
amg-837 AMG-837: GPR40 agonist	2.31	1
N-[(1R)-2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-2-furancarboxamide [no description available]	2.31	1	aromatic amide; furans
bictegravir bictegravir: HIV Integrase Inhibitors. bictegravir : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1.	2.31	1	monocarboxylic acid amide; organic heterotetracyclic compound; secondary carboxamide; trifluorobenzene	HIV-1 integrase inhibitor
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	2.31	1	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
amg531 [no description available]	2.31	1
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-cyclohexyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-alaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.53 muM).	2.31	1	aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 1H-indole-2-carboxylic acid with the primary amino group of 3-fluoro-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide. It is an inhibitor of SARS coronavirus main proteinase and inhibits SARS-CoV-2 replication in cell culture (EC50 = 0.72 muM).	2.31	1	aldehyde; indolecarboxamide; monofluorobenzenes; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Carbohydrate-Deficient Glycoprotein Syndrome [description not available]	2.06	1
Congenital Disorders of Glycosylation A genetically heterogeneous group of heritable disorders resulting from defects in protein N-glycosylation.	2.06	1
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	2.1	1
Hepatocellular Carcinoma [description not available]	2.1	1
Cancer of Liver [description not available]	2.1	1
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	2.1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.1	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.1	1
Leishmania Infection [description not available]	3.12	1
Infections, Plasmodium [description not available]	3.12	1
Histomoniasis [description not available]	3.12	1
African Sleeping Sickness [description not available]	3.12	1
American Trypanosomiasis [description not available]	3.12	1
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	3.12	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	3.12	1
Trypanosomiasis, African A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.	3.12	1
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	3.12	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.97	1

2-phenyl-1,2-benzisothiazol-3-(2h)-one

Description

Cross-References

Synonyms (37)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (81)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (222)

Molecular Functions (82)

Ceullar Components (54)

Bioassays (104)

Research

Studies (23)

Market Indicators

Research Demand Index: 11.78

Study Types

2-phenyl-1,2-benzisothiazol-3-(2h)-one

Description

Cross-References

Synonyms (37)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (81)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (222)

Molecular Functions (82)

Ceullar Components (54)

Bioassays (104)

Research

Studies (23)

Market Indicators

Research Demand Index: 11.78

Study Types

Related Drugs (146)

Related Conditions (20)